Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
Scienture Holdings (NASDAQ: SCNX), a specialty pharma company focused on novel brand products, has announced its upcoming participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. The company's management team will present their corporate strategy and conduct one-on-one meetings with institutional and individual investors to discuss recent developments, growth plans, and investment opportunities.
Scienture Holdings (NASDAQ: SCNX), un'azienda farmaceutica specializzata in prodotti di marca innovativi, ha annunciato la sua prossima partecipazione a The Microcap Conference 2025. L'evento si terrà dal 28 al 30 gennaio 2025, presso il Borgata Hotel Spa & Casino ad Atlantic City, NJ. Il team di gestione dell'azienda presenterà la propria strategia aziendale e condurrà incontri individuali con investitori istituzionali e privati per discutere degli sviluppi recenti, dei piani di crescita e delle opportunità di investimento.
Scienture Holdings (NASDAQ: SCNX), una empresa farmacéutica especializada en productos de marca novedosos, ha anunciado su próxima participación en The Microcap Conference 2025. El evento se llevará a cabo del 28 al 30 de enero de 2025, en el Borgata Hotel Spa & Casino en Atlantic City, NJ. El equipo directivo de la empresa presentará su estrategia corporativa y llevará a cabo reuniones individuales con inversores institucionales y particulares para discutir desarrollos recientes, planes de crecimiento y oportunidades de inversión.
Scienture Holdings (NASDAQ: SCNX), 혁신적인 브랜드 제품에 집중하는 전문 제약 회사가 The Microcap Conference 2025에 참가한다고 발표했습니다. 이 행사는 2025년 1월 28일부터 30일까지 뉴저지 애틀랜틱시티의 Borgata Hotel Spa & Casino에서 열릴 예정입니다. 회사의 경영진은 그들의 기업 전략을 발표하고 최근 개발 사항, 성장 계획 및 투자 기회에 대해 논의하기 위해 기관 및 개인 투자자와의 일대일 회의를 진행할 것입니다.
Scienture Holdings (NASDAQ: SCNX), une société pharmaceutique spécialisée dans les produits de marque novateurs, a annoncé sa prochaine participation à The Microcap Conference 2025. L'événement se déroulera du 28 au 30 janvier 2025, au Borgata Hotel Spa & Casino à Atlantic City, NJ. L'équipe de direction de l'entreprise présentera sa stratégie d'entreprise et organisera des réunions individuelles avec des investisseurs institutionnels et particuliers pour discuter des développements récents, des plans de croissance et des opportunités d'investissement.
Scienture Holdings (NASDAQ: SCNX), ein spezialisiertes Pharmaunternehmen, das sich auf innovative Markenprodukte konzentriert, hat seine bevorstehende Teilnahme an The Microcap Conference 2025 angekündigt. Die Veranstaltung findet vom 28. bis 30. Januar 2025 im Borgata Hotel Spa & Casino in Atlantic City, NJ, statt. Das Management-Team des Unternehmens wird seine Unternehmensstrategie präsentieren und Einzelgespräche mit institutionellen und privaten Investoren führen, um über aktuelle Entwicklungen, Wachstumspläne und Investitionsmöglichkeiten zu sprechen.
- None.
- None.
TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the “Company”) (NASDAQ: SCNX), a specialty pharma company with a novel pipeline of brand products, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
The Company’s management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the Company’s recent developments, growth strategy, and investment opportunities.
About The Microcap Conference 2025
The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.
The 2025 event will feature:
- Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC’s Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.
- Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.
- Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.
Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. For more information, visit https://themicrocapconference.com.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Our products in development at Scienture, LLC, are across therapeutic areas, indications and cater to different market segments and channels. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contacts:
SCIENTURE HOLDINGS, INC.
SCIENTURE HOLDINGS, INC.
6308 Benjamin Rd, Suite 708
Tampa, Florida 33634
Phone: (866) 468-6535
Email: IR@Scienture.com
FAQ
When is Scienture Holdings (SCNX) presenting at The Microcap Conference 2025?
What will Scienture Holdings (SCNX) discuss at The Microcap Conference 2025?
Where will The Microcap Conference 2025 featuring SCNX be held?
What type of meetings will SCNX conduct at The Microcap Conference 2025?
